Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

NCT02184572 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1742

Enrollment

INDUSTRY

Sponsor class

Conditions

Measles; Mumps; Rubella
Measles-Mumps-Rubella Vaccine

Interventions

BIOLOGICAL: Priorix
BIOLOGICAL: M-M-R II
BIOLOGICAL: Varivax
BIOLOGICAL: Havrix
BIOLOGICAL: Prevnar 13

Sponsor

GlaxoSmithKline